{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:05:36Z","timestamp":1782443136130,"version":"3.54.5"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1159579"],"award-info":[{"award-number":["GNT1159579"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1184428"],"award-info":[{"award-number":["GNT1184428"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2007007"],"award-info":[{"award-number":["GNT2007007"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ijantimicag.2024.107161","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T16:24:12Z","timestamp":1711815852000},"page":"107161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing"],"prefix":"10.1016","volume":"63","author":[{"given":"Siobhonne K.J.","family":"Breen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-0311","authenticated-orcid":false,"given":"Marina","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"L\u00f3pez-Causap\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Tait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Smallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-4516","authenticated-orcid":false,"given":"Yinzhi","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee L.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7352-3097","authenticated-orcid":false,"given":"Jurgen B.","family":"Bulitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-8590","authenticated-orcid":false,"given":"Roger L.","family":"Nation","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0928-4743","authenticated-orcid":false,"given":"Cornelia B.","family":"Landersdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107161_bib0001","first-page":"194","volume":"15","author":"Lyczak","year":"2002"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0002","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1128\/AAC.01566-16","article-title":"Population pharmacokinetics and safety of ceftolozane-tazobactam in adult cystic fibrosis patients admitted with acute pulmonary exacerbation","volume":"60","author":"Monogue","year":"2016","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0003","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00138-18","article-title":"Cystic fibrosis and Pseudomonas aeruginosa: the host-microbe interface","volume":"32","author":"Malhotra","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102262","article-title":"The changing landscape of the cystic fibrosis lung environment: From the perspective of Pseudomonas aeruginosa","volume":"65","author":"Greenwald","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0005","unstructured":"World Health Organisation. WHO publishes list of bacteria for which new antibiotics are urgently needed. World Health Organisation; 2017."},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0006","doi-asserted-by":"crossref","first-page":"8671","DOI":"10.3390\/ijms21228671","article-title":"Pseudomonas aeruginosa Biofilms","volume":"21","author":"Thi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0007","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/CPM.0000000000000108","article-title":"Understanding Persistent bacterial lung infections","volume":"23","author":"Pragman","year":"2016","journal-title":"Clin Pulm Med"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/759348","article-title":"The formation of biofilms by Pseudomonas aeruginosa: a review of the natural and synthetic compounds interfering with control mechanisms","volume":"2015","author":"Rasamiravaka","year":"2015","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0009","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1126\/science.288.5469.1251","article-title":"High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection","volume":"288","author":"Oliver","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0010","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1038\/s41598-017-05621-5","article-title":"Evolution of the Pseudomonas aeruginosa mutational resistome in an international cystic fibrosis clone","volume":"7","author":"L\u00f3pez-Causap\u00e9","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0011","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1128\/AAC.49.6.2276-2282.2005","article-title":"Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation","volume":"49","author":"Ciofu","year":"2005","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0012","doi-asserted-by":"crossref","first-page":"e02538","DOI":"10.1128\/AAC.02538-18","article-title":"Characterization of hypermutator Pseudomonas aeruginosa isolates from patients with cystic fibrosis in australia","volume":"63","author":"Rees","year":"2019","journal-title":"Antimicrobial Agent Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0013","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ijmm.2010.08.009","article-title":"Mutators in cystic fibrosis chronic lung infection: prevalence, mechanisms, and consequences for antimicrobial therapy","volume":"300","author":"Oliver","year":"2010","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0014","doi-asserted-by":"crossref","first-page":"e00469","DOI":"10.1128\/AAC.00469-20","article-title":"Clinically relevant epithelial lining fluid concentrations of meropenem with ciprofloxacin provide synergistic killing and resistance suppression of hypermutable Pseudomonas aeruginosa in a dynamic biofilm model","volume":"64","author":"Bilal","year":"2020","journal-title":"Antimicrobial Agent Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0015","article-title":"Pulmonary exacerbations clinical care guidelines","author":"West","year":"2021","journal-title":"Cystic Fibrosis Foundation"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0016","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chest.2020.09.084","article-title":"Pulmonary exacerbations in adults with cystic fibrosis: a grown-up issue in a changing cystic fibrosis landscape","volume":"159","author":"Stanford","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0017","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0018","doi-asserted-by":"crossref","first-page":"e01293","DOI":"10.1128\/AAC.01293-19","article-title":"Synergistic meropenem-tobramycin combination dosage regimens against clinical hypermutable Pseudomonas aeruginosa at simulated epithelial lining fluid concentrations in a dynamic biofilm model","volume":"63","author":"Bilal","year":"2019","journal-title":"Antimicrobial Agent Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0019","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/pharmaceutics11090470","article-title":"Evaluation of tobramycin and ciprofloxacin as a synergistic combination against hypermutable Pseudomonas aeruginosa strains via mechanism-based modelling","volume":"11","author":"Rees","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0020","doi-asserted-by":"crossref","first-page":"e01150","DOI":"10.1128\/AAC.01150-18","article-title":"Meropenem combined with ciprofloxacin combats hypermutable Pseudomonas aeruginosa from respiratory infections of cystic fibrosis patients","volume":"62","author":"Rees","year":"2018","journal-title":"Antimicrobial Agent Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0021","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/CE.S11181","article-title":"Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review","volume":"6","author":"Kirkby","year":"2011","journal-title":"Core Evidence"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0022","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/antibiotics10030338","article-title":"Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives","volume":"10","author":"Taccetti","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0023","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1093\/jac\/dks296","article-title":"In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells","volume":"67","author":"Yu","year":"2012","journal-title":"J Antimicrobial Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0024","article-title":"Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis","volume":"8","author":"Smith","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0025","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1128\/AAC.00196-16","article-title":"Sequential treatment of biofilms with aztreonam and tobramycin is a novel strategy for combating Pseudomonas aeruginosa chronic respiratory infections","volume":"60","author":"Rojo-Molinero","year":"2016","journal-title":"Antimicrobial Agent Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0026","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2024"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0027","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0028","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1128\/AAC.02231-15","article-title":"Suppression of emergence of resistance in pathogenic bacteria: keeping our powder dry, part 2","volume":"60","author":"Drusano","year":"2016","journal-title":"Antimicrobial Agent Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0029","doi-asserted-by":"crossref","first-page":"e01679","DOI":"10.1128\/AAC.01679-19","article-title":"Meropenem-tobramycin combination regimens combat carbapenem-resistant Pseudomonas aeruginosa in the hollow-fiber infection model simulating augmented renal clearance in critically Ill patients","volume":"64","author":"Yadav","year":"2019","journal-title":"Antimicrobial Agent Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02203-21","article-title":"Simulated intravenous versus inhaled tobramycin with or without intravenous ceftazidime evaluated against hypermutable Pseudomonas aeruginosa via a dynamic biofilm model and mechanism-based modeling","volume":"66","author":"Bilal","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106887","article-title":"Ceftolozane\/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: resistance mechanisms and synergistic activity","volume":"62","author":"Agyeman","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0032","doi-asserted-by":"crossref","unstructured":"Tait JR, Harper M, Cort\u00e9s-Lara S, Rogers KE, L\u00f3pez-Causap\u00e9 C, Smallman TR, et al. Ceftolozane-tazobactam against Pseudomonas aeruginosa cystic fibrosis clinical isolates in the hollow-fiber infection model: challenges imposed by hypermutability and heteroresistance. Antimicrobial Agent Chemother 67:e0041423.","DOI":"10.1128\/aac.00414-23"},{"issue":"4","key":"10.1016\/j.ijantimicag.2024.107161_bib0033","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02583-17","article-title":"Evolution of the Pseudomonas aeruginosa Aminoglycoside Mutational Resistome In Vitro and in the Cystic Fibrosis Setting","volume":"62","author":"L\u00f3pez-Causap\u00e9","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0034","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.mib.2011.01.002","article-title":"Phase variation: how to create and coordinate population diversity","volume":"14","author":"van der Woude","year":"2011","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.chembiol.2016.12.015","article-title":"Carbon sources tune antibiotic susceptibility in Pseudomonas aeruginosa via tricarboxylic acid cycle control","volume":"24","author":"Meylan","year":"2017","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0036","first-page":"e03239","article-title":"Pseudomonas aeruginosa citrate synthase GltA influences antibiotic tolerance and the type III secretion system through the stringent response","volume":"11","author":"Chen","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0037","doi-asserted-by":"crossref","first-page":"21748","DOI":"10.1073\/pnas.1912345116","article-title":"A small-molecule inhibitor of BamA impervious to efflux and the outer membrane permeability barrier","volume":"116","author":"Hart","year":"2019","journal-title":"Proceed Nation Acad Sci"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0038","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1574-6968.2009.01651.x","article-title":"The major outer membrane protein OprG of Pseudomonas aeruginosa contributes to cytotoxicity and forms an anaerobically regulated, cation-selective channel","volume":"296","author":"McPhee","year":"2009","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0039","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3389\/fmicb.2020.01681","article-title":"Identification of genes required for resistance to peptidomimetic antibiotics by transposon sequencing","volume":"11","author":"Vitale","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0040","doi-asserted-by":"crossref","first-page":"41178","DOI":"10.1038\/srep41178","article-title":"The aliphatic amidase AmiE is involved in regulation of Pseudomonas aeruginosa virulence","volume":"7","author":"Clamens","year":"2017","journal-title":"Scientif Rep"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0041","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/mmi.13077","article-title":"The cell wall amidase AmiB is essential for Pseudomonas aeruginosa cell division, drug resistance and viability","volume":"97","author":"Yakhnina","year":"2015","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0042","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1128\/AAC.05829-11","article-title":"PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients","volume":"56","author":"Moskowitz","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0043","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02583-17","article-title":"Evolution of the Pseudomonas aeruginosa aminoglycoside mutational resistome in vitro and in the cystic fibrosis setting","volume":"62","author":"L\u00f3pez-Causap\u00e9","year":"2018","journal-title":"Antimicrobial Agent Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0044","doi-asserted-by":"crossref","first-page":"10081","DOI":"10.1074\/jbc.RA120.013295","article-title":"The ThiL enzyme is a valid antibacterial target essential for both thiamine biosynthesis and salvage pathways in Pseudomonas aeruginosa","volume":"295","author":"Kim","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41598-018-37422-9","article-title":"Virulence characteristics and an action mode of antibiotic resistance in multidrug-resistant Pseudomonas aeruginosa","volume":"9","author":"Hwang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0046","doi-asserted-by":"crossref","first-page":"12615","DOI":"10.1038\/s41598-017-12667-y","article-title":"Targeting the alternative sigma factor RpoN to combat virulence in Pseudomonas aeruginosa","volume":"7","author":"Lloyd","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0047","doi-asserted-by":"crossref","first-page":"e18184","DOI":"10.1371\/journal.pone.0018184","article-title":"The Pseudomonas aeruginosa chemotaxis methyltransferase CheR1 impacts on bacterial surface sampling","volume":"6","author":"Schmidt","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0048","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JB.183.3.813-820.2001","article-title":"Essential PchG-dependent reduction in pyochelin biosynthesis of Pseudomonas aeruginosa","volume":"183","author":"Reimmann","year":"2001","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0049","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1128\/JB.00010-09","article-title":"The Pseudomonas aeruginosa pyochelin-iron uptake pathway and its metal specificity","volume":"191","author":"Braud","year":"2009","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.femsle.2005.04.010","article-title":"The Pseudomonas aeruginosa pirA gene encodes a second receptor for ferrienterobactin and synthetic catecholate analogues","volume":"246","author":"Ghysels","year":"2005","journal-title":"FEMS Microbiol Lett"},{"issue":"2","key":"10.1016\/j.ijantimicag.2024.107161_bib0051","doi-asserted-by":"crossref","first-page":"e02838","DOI":"10.1128\/mBio.02838-18","article-title":"Pseudomonas savastanoi Two-Component System RhpRS Switches between Virulence and Metabolism by Tuning Phosphorylation State and Sensing Nutritional Conditions","volume":"10","author":"Xie","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0052","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01376-18","article-title":"CdrA interactions within the Pseudomonas aeruginosa biofilm matrix safeguard it from proteolysis and promote cellular packing","volume":"9","author":"Reichhardt","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0053","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1365-2958.2009.06991.x","article-title":"Pseudomonas aeruginosa uses a cyclic-di-GMP-regulated adhesin to reinforce the biofilm extracellular matrix","volume":"75","author":"Borlee","year":"2010","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0054","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01049-18","article-title":"The PA3177 gene encodes an active diguanylate cyclase that contributes to biofilm antimicrobial tolerance but not biofilm formation by Pseudomonas aeruginosa","volume":"62","author":"Poudyal","year":"2018","journal-title":"Antimicrobial Agent Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0055","first-page":"e00722","article-title":"Aminoglycoside concentrations required for synergy with carbapenems against Pseudomonas aeruginosa determined via mechanistic studies and modeling","volume":"61","author":"Yadav","year":"2017","journal-title":"Antimicrobial Agent Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107161_bib0056","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.mib.2013.06.010","article-title":"PK\/PD models in antibacterial development","volume":"16","author":"Velkov","year":"2013","journal-title":"Curr Opin Microbiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924000797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924000797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T16:52:29Z","timestamp":1716828749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924000797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0924857924000797"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107161","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107161"}}